Evolus (EOLS) Total Current Liabilities (2017 - 2026)
Evolus (EOLS) posted Total Current Liabilities of $68.0 million for Q1 2026, down 9.67% on a QoQ basis from $75.3 million in Q4 2025, and up 20.97% year-over-year from $56.2 million in Q1 2025.
Evolus (EOLS) Total Current Liabilities (2017 - 2026) Analysis & Trends
Evolus' Total Current Liabilities history runs 10 years deep, the most recent figure standing at $68.0 million for Q1 2026.
- Quarterly Total Current Liabilities rose 20.97% year-over-year to $68.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.0 million (up 20.97% YoY) and the FY2025 annual result came in at $75.3 million, up 19.61% from the prior year.
- Total Current Liabilities was $68.0 million for Q1 2026 at Evolus, down from $75.3 million in the prior quarter.
- Across five years, Total Current Liabilities topped out at $75.3 million in Q4 2025 and bottomed at $40.7 million in Q1 2023.
- A 5-year average of $54.3 million and a median of $51.5 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities plunged 53.56% — and 2024, when it surged 30.88%.
- Evolus' Total Current Liabilities stood at $46.5 million in 2022, then gained by 3.83% to $48.3 million in 2023, then jumped by 30.38% to $63.0 million in 2024, then climbed by 19.61% to $75.3 million in 2025, then decreased by 9.67% to $68.0 million in 2026.
- Business Quant data shows EOLS's Total Current Liabilities at $68.0 million in Q1 2026, $75.3 million in Q4 2025, and $66.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 6.56 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.53 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 2.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 18.06 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 6.81 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 831.70 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 1.66 Bn |
| 10 | Evolus | 390.47 Mn | 340.68 Mn | 48.90 Mn | 68.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 68.02 Mn |
| Dec 31, 2025 | 75.31 Mn |
| Sep 30, 2025 | 66.71 Mn |
| Jun 30, 2025 | 63.75 Mn |
| Mar 31, 2025 | 56.23 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Sep 30, 2024 | 60.82 Mn |
| Jun 30, 2024 | 54.12 Mn |
| Mar 31, 2024 | 46.80 Mn |
| Dec 31, 2023 | 48.29 Mn |
| Sep 30, 2023 | 48.54 Mn |
| Jun 30, 2023 | 41.35 Mn |
| Mar 31, 2023 | 40.68 Mn |
| Dec 31, 2022 | 46.51 Mn |
| Sep 30, 2022 | 51.27 Mn |
| Jun 30, 2022 | 51.53 Mn |
| Mar 31, 2022 | 40.70 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 71.30 Mn |
| Jun 30, 2021 | 87.29 Mn |